Abrégé

Provided herein are supplements that include free amino acids L-glutamine or a salt thereof, L-leucine or a salt thereof, nd L-arginine or a salt thereof, and active IGF-1. The L-glutamine or salt thereof, L-leucine or salt thereof, and L-arginine or salt thereof can be present at a ratio of approximately 3:1:1. Also provided are compositions that include the supplement, such as a food product. The disclosure also includes, but is not limited to, methods for using the supplements, including improving the performance of an animal, improving a processing factor of an animal, or increasing intestinal health of an animal, where the method includes administering to the animal a food product that has the supplement.

Classes IPC  ?

• A23K 20/142 - Acides aminésLeurs dérivés
• A23K 20/184 - Hormones
• A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
• A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille

Abrégé

Provided herein are supplements that include free amino acids L-glutamine or a salt thereof, L-leucine or a salt thereof, and L-arginine or a salt thereof, and active IGF-1. The L-glutamine or salt thereof, L-leucine or salt thereof, and L-arginine or salt thereof can be present at a ratio of approximately 3:1:1. Also provided are compositions that include the supplement, such as a food product. The disclosure also includes, but is not limited to, methods for using the supplements, including improving the performance of an animal, improving a processing factor of an animal, or increasing intestinal health of an animal, where the method includes administering to the animal a food product that has the supplement.

Classes IPC  ?

• A23K 20/142 - Acides aminésLeurs dérivés
• A23K 20/184 - Hormones
• A23K 50/30 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les porcs
• A23K 50/60 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux sevrés
• A23K 50/75 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les oiseaux pour la volaille
• A23L 33/17 - Acides aminés, peptides ou protéines
• A23L 33/175 - Acides aminés
• A23L 33/195 - Protéines de micro-organismes
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2

Produits et services

Animal feed supplements

Produits et services

Animal feed supplements; nutritional supplements for animal consumption.

Produits et services

Animal feed supplements; Nutritional supplements for animal consumption

Abrégé

Provided herein are methods for treating an animal using a composition that includes active IGF. The methods include treating an animal at risk of having an infection caused by an infectious agent, treating an animal having an infection, and treating a symptom associated with an infection. In one embodiment, the infectious agent is a virus. In one embodiment, the administering includes daily administration of at least 0.05 nanograms of active IGF-1 per kilogram bodyweight of the animal daily (ng/kg), at least 0.1 ng/kg, at least 2 ng/kg, at least 5 ng/kg, or at least 10 ng/kg.

Classes IPC  ?

• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• A23K 20/147 - Dérivés polymériques, p. ex. peptides ou protéines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Produits et services

Nutritional supplements for human and animal consumption.

Produits et services

Nutritional supplements for human and animal consumption.

Produits et services

Nutritional supplements for human and animal consumption.

Abrégé

Provided herein are methods for altering a characteristic of an offspring or a litter. The method can include administering an effective amount of a composition that includes active IGF-1 to a pregnant animal, wherein a characteristic of an offspring of the pregnant animal is altered compared to a control offspring. In another embodiment, the animal is a lactating animal, wherein a characteristic of an offspring nursed by the lactating animal is altered compared to a control offspring. Examples of characteristics that can be altered include increased survival of offspring before weaning, increased weight of offspring at weaning, increased weight of offspring at end of growing phase, increased average daily gain, and increased average daily food intake. In another embodiment, a characteristic of a litter can be altered, such as increased number of offspring born alive, increased litter birth weight, increased offspring birth weight, reduced number of stillborn offspring, or a combination thereof.

Classes IPC  ?

• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2

Abrégé

Provided herein are methods for altering a characteristic of an offspring or a litter. The method can include administering an effective amount of a composition that includes active IGF-1 to a pregnant animal, wherein a characteristic of an offspring of the pregnant animal is altered compared to a control offspring. In another embodiment, the animal is a lactating animal, wherein a characteristic of an offspring nursed by the lactating animal is altered compared to a control offspring. Examples of characteristics that can be altered include increased survival of offspring before weaning, increased weight of offspring at weaning, increased weight of offspring at end of growing phase, increased average daily gain, and increased average daily food intake. In another embodiment, a characteristic of a litter can be altered, such as increased number of offspring born alive, increased litter birth weight, increased offspring birth weight, reduced number of stillborn offspring, or a combination thereof.

Classes IPC  ?

• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2

Abrégé

Provided wherein are methods for treating inflammation. In one embodiment, the method includes administering an effective amount of a composition to a subject having or at risk of having a condition that includes inflammation. The condition can be arthritis, tendonitis, osteoarthritis, fibrosis, shingles, psoriasis, acne, or dermatitis. Examples of dermatitis include atopic dermatitis, contact dermatitis, and seborrhoeic dermatitis. In one embodiment, the method includes administering an effective amount of a composition to a subject having pain, heat, and/or redness associated with inflammation. In one embodiment, the composition administered can include active TGF-β at a concentration of at least 0.001 nanograms/gram (ng/g). Optionally, the active TGF-β can be at a concentration of no greater than 4000 ng/g.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Abrégé

Provided herein are methods for increasing the concentration of insulin-like growth factor (IGF) in the serum of a subject. In one embodiment, the method includes administering active IGF-1 to a subject, wherein the concentration of IGF in the serum of the subject is increased. Also provided are methods for treating a condition in a subject, methods for improving or maintaining the health of a subject, and methods for improving a characteristic of a subject. Examples of conditions include a motor neuron disorder, Alzheimer's disease, myocardial infarction, hypoxic-ischemic brain injury, osteoporosis, skeletal muscle repair, and growth failure. Examples of characteristics include increased milk production, increased fertilization, increased reproduction, increased growth, increased oocyte quality in a ruminant undergoing superovulation, and increased embryo viability. In one embodiment, the IGF-1 administered to the subject is obtained from a natural source that has been processed to increase the amount of active IGF-1.

Classes IPC  ?

• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

Provided herein are methods for increasing the concentration of insulin-like growth factor (IGF) in the serum of a subject. In one embodiment, the method includes administering active IGF-1 to a subject, wherein the concentration of IGF in the serum of the subject is increased. Also provided are methods for treating a condition in a subject, methods for improving or maintaining the health of a subject, and methods for improving a characteristic of a subject. Examples of conditions include a motor neuron disorder, Alzheimer's disease, myocardial infarction, hypoxic-ischemic brain injury, osteoporosis, skeletal muscle repair, and growth failure. Examples of characteristics include increased milk production, increased fertilization, increased reproduction, increased growth, increased oocyte quality in a ruminant undergoing superovulation, and increased embryo viability. In one embodiment, the IGF-1 administered to the subject is obtained from a natural source that has been processed to increase the amount of active IGF-1.

Classes IPC  ?

• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Produits et services

Nutritional supplements for human and animal consumption

Abrégé

Provided herein are methods for treating an animal using a composition that includes active IGF. The methods include treating an animal at risk of having an infection caused by an infectious agent, treating an animal having an infection, and treating a symptom associated with an infection. In one embodiment, the infectious agent is a virus. In one embodiment, the administering includes daily administration of at least 0.05 nanograms of active IGF-1 per kilogram bodyweight of the animal daily (ng/kg), at least 0.1 ng/kg, at least 2 ng/kg, at least 5 ng/kg, or at least 10 ng/kg.

Classes IPC  ?

• A61K 38/30 - Facteurs de croissance analogues à l'insuline, c.-à-d. somatomédines, p. ex. IGF-1, IGF-2
• A61P 31/12 - Antiviraux

Abrégé

Provided herein are methods for treating an animal using a composition that includes active IGF. The methods include treating an animal at risk of having an infection caused by an infectious agent, treating an animal having an infection, and treating a symptom associated with an infection. In one embodiment, the infectious agent is a virus. In one embodiment, the administering includes daily administration of at least 0.05 nanograms of active IGF-1 per kilogram bodyweight of the animal daily (ng/kg), at least 0.1 ng/kg, at least 2 ng/kg, at least 5 ng/kg, or at least 10 ng/kg.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

A feeding composition including activated growth factor(s) increases feed to gain ratio, increases overall weight gain, reduces necessary antibiotic or electrolyte therapy and reduces mortality in animals. The composition is derived by first separating growth factor(s) from a source such as whey or blood, then subjecting the factor to an activation process, and then providing the activated growth factor to the animal. A feed additive comprising activated growth factors in appropriate amounts, shows results that are an improvement over standard therapies of supplementation. Application of activated growth factors may be by topical, injection or oral application.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides

Produits et services

Animal feed supplements